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Abstract: Estrogen receptor (ER)-positive progesterone receptor (PR)-negative breast cancers are 
infrequent but clinically challenging. Despite the volume of genomic data available on these tumors, 
their biology remains poorly understood. Here, we aimed to identify clinically relevant subclasses 
of ER+/PR− breast cancers based on their mutational landscape. The Cancer Genomics Data Server 
was interrogated for mutational and clinical data of all ER+ breast cancers with information on PR 
status from The Cancer Genome Atlas (TCGA), Memorial Sloan Kettering (MSK), and Molecular 
Taxonomy of Breast Cancer International Consortium (METABRIC) projects. Clustering analysis 
was performed using gplots, ggplot2, and ComplexHeatmap packages. Comparisons between 
groups were performed using the Student’s t-test and the test of Equal or Given Proportions. 
Survival curves were built according to the Kaplan–Meier method; differences in survival were 
assessed with the log-rank test. A total of 3570 ER+ breast cancers (PR− n = 959, 27%; PR+ n = 2611, 
73%) were analyzed. Mutations in well-known cancer genes such as TP53, GATA3, CDH1, HER2, 
CDH1, and BRAF were private to or enriched for in PR− tumors. Mutual exclusivity analysis 
revealed the presence of four molecular clusters with significantly different prognosis on the basis 
of PIK3CA and TP53 status. ER+/PR− breast cancers are genetically heterogeneous and encompass 
a variety of distinct entities in terms of prognostic and predictive information. 
Keywords: breast cancer; progesterone receptor negative; mutational profiling; PI3K pathway; TP53 
 
1. Introduction 
Estrogen receptor (ER)-positive progesterone receptor (PR)-negative (ER+/PR−) breast cancers 
are a subset of Luminal B tumors characterized by the strong and diffuse nuclear expression of ER-
alpha but not of PR [1]. They account for 5% of all invasive breast cancers and show a relatively 
aggressive clinical course compared to ER+/PR+ neoplasms [1–5]. ER+/PR− invasive breast cancers 
are described as larger in size than PR+ carcinomas and are generally of no special histological type 
(i.e., ductal) [1,6]. Even though they preferentially affect postmenopausal women, these diagnoses 
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are not exceptional in younger patients [1,2,7]. As confirmed by several prospectively randomized 
controlled neoadjuvant trials, ER+/PR− breast cancers are associated with a higher response but also 
worse long-term outcome after neoadjuvant therapy [5]. There are several lines of evidence to suggest 
that the worse prognosis of ER+/PR− tumors may be related to the phenomena of hormone therapy 
resistance [1–5]. However, a large adjuvant trial on the use of aromatase inhibitors in postmenopausal 
women with early breast cancer revealed that the PR status has no effect on the relative efficacy of 
this therapy [8]. For this reason, some authors have questioned the clinical utility of PR testing [9]. To 
date, hormonal therapy remains recommended in ER+ tumors regardless of PR status [10]. All these 
diverse correlations highlight the clinical challenges provided by ER+/PR− breast cancers. 
A proportion of ER+/PR− neoplasms shows a remarkable degree of genomic instability, reaching 
almost twice the DNA copy number variations and tumor mutational load than those of both 
ER+/PR+ and ER− breast cancers [1,8]. Furthermore, many growth factors were observed to be 
overexpressed in these tumors, such as HER family, PI3K, Akt, and src [1,2,11–13]. These pathways, 
which can also be altered in ER+/PR+ tumors, are known to be involved in ER phosphorylation, which 
may lead to ligand-independent activation [14]. There is also evidence that the upregulation of Akt 
and HER1/2 is implicated in tamoxifen resistance [1,2,11,12,15–18]. Recently, PR has been proposed 
as a surrogate biomarker of altered growth factor signaling [5]. Due to these insights, and the 
substantial lack of distinct biological properties identified to date in ER+/PR− breast cancers, it is 
becoming increasingly clear that these tumors are clinically and biologically heterogeneous [19–25].  
During the past few years, the Cancer Genome Atlas (TCGA) project has exposed the complexity 
of the genome-wide genetic alterations in breast cancer [26]. On the other hand, the proper clinical 
management of Luminal (i.e., ER+) breast cancers, particularly in intermediate-risk patients, remains 
a matter of controversy. However, there is a limited understanding of how the mutational landscape 
of these tumors, according to the PR status, can be exploited in the clinic to allow for more tailored 
management schemes. In this study, we sought: (i) to characterize the mutational signatures of 
ER+/PR− breast cancers; (ii) to compare the molecular landscapes of PR− and PR+ Luminal tumors; 
and (iii) to define the prognostic value of the type and pattern of somatic genetic alterations in these 
patients. 
2. Results 
A total of 3589 ER+ breast cancers from the publicly available datasets TCGA, Memorial Sloan 
Kettering (MSK), and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) 
were identified. Among them, 3570 (99.5%) cases (2815 invasive ductal carcinomas and 755 invasive 
carcinomas of any special type) had information on PR status (PR− n = 959, 27%; PR+ n = 2611, 73%) 
and were included in the current study. The median age at diagnosis of PR− tumors was 59 years old 
(range 24–92); for PR+ tumors, it was 57 years old (range 23–91). Taken together, 53,585 mutations 
targeting 13,402 genes were identified, including 57,448 (99%), 6642 (90%), and 8905 (89%) mutations 
that were private to only one sample in the TCGA, MSK, and METABRIC cohorts, respectively. The 
number of samples, mutated genes, and mutations of the tumors included in the analysis are 
summarized in Table 1 and Table S1.  
Table 1. Number ER+ breast cancer samples, according to the PR status from the TCGA, MSK, and 
METABRIC projects. PR, progesterone receptor. 
 TCGA (%) MSK (%) METABRIC (%) 
PR− (n = 959) 110 (12) 396 (41) 453 (47) 
PR+ (n = 2611) 608 (23) 1031 (40) 972 (37) 
Total (n = 3570) 718 (20) 1427 (40) 1425 (40) 
2.1. The Molecular Landscape of ER+/PR− Breast Cancers 
The average number of mutations displayed by ER+/PR− breast cancers was 16 per sample, 
whereas in PR+ tumors was 14. The two groups shared 5668 mutated genes, while approximately 
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1319 (19%) genes were found to be privately altered in ER+/PR− breast cancers. Overall, the mutations 
in PR− tumors were missense in 12,583 (78%), nonsense in 1250 (8%), frameshift deletions in 896 (5%), 
frameshift insertions in 616 (4%), splicing in 516 (3%), and in-frame indels in 261 (2%) cases. Of note, 
fusion genes were detected in 69 ER+/PR− tumors. The mutational landscape and selected 
clinicopathologic features in ER+/PR− and ER+/PR+ breast cancers are depicted in Figure 1 and Figure 
S1, respectively.  
 
Figure 1. Oncoprint visualization of highly recurrent somatic molecular alterations in ER+/PR− breast 
cancers (959 samples). Each row represents a gene, as reported on the right, and was sorted by gene 
alterations frequency (bar plot on the right); types of alterations are color-coded on the basis of the 
legend on the bottom. Each column represents a sample and was sorted to appreciate the mutual 
exclusivity across genes. The bar plot on the top represents the number of samples showing alterations 
in the displayed genes. Cluster analysis, human epidermal growth factor receptor (HER)2 status, 
histological type, tumor stage, menopause status, and age at diagnosis are reported as rows at the 
bottom of the figure. Clustering was performed according to the mutual exclusivity and patterns of 
mutations. 
The most frequently mutated gene in PR− tumors was phosphatidylinositol-4,5-bisphosphate 3-
kinase, catalytic subunit alpha (PIK3CA), with lower prevalence than in PR+ tumors (n = 354, 37% vs. 
n = 1220, 47%; p < 0.01). In particular, the vast majority of PIK3CA mutations were missense and 
affected four hotspot regions of the gene, namely N345K, E542K, E545K, and H1047R (Figure 2). 
Notably, the H1047R and E545K mutations in PIK3CA were less frequent in PR− tumors (Table 2). 
The prevalence of samples showing mutations in TP53, which was the second most frequently 
mutated gene in both PR− and PR+ Luminal tumors, was higher in PR− breast cancers (n = 312, 33% 
vs. n = 496, 19%; p < 0.01). Furthermore, the nonsense mutation R342X and the missense mutations 
P728S, I195T, and H179R in TP53 were enriched in PR− tumors (p < 0.05), as shown in Table 2. Taken 
together, PIK3CA and TP53 status allowed for the definition of four molecular clusters (Figure 1). 
Specifically, Cluster 1 included all PIK3CA-mutant/TP53-mutant samples (n = 108, 11%), Cluster 2 all 
PIK3CA-mutant/TP53 wild-type samples (n = 246, 26%), Cluster 3 PIK3CA wild-type/TP53-mutant 
tumors (n = 204, 21%), and Cluster 4 encompassed all PIK3CA/TP53 wild-type cases (n = 401, 42%). 
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Among the other recurrent gene alterations, the hotspot mutation E17K in RAC-alpha 
serine/threonine-protein kinase (AKT1), which was present in 3% and 5% of PR− and PR+ cases, 
respectively, was mutually exclusive with mutations targeting PIK3CA, regardless of PR status 
(Figure S2). On the other hand, even if PIK3CA and AKT1 were observed to be recurrently mutated 
in both groups, the hotspot regions differed significantly on the basis of PR activation (p < 0.05). Of 
note, GATA3 showed a high number of frame-shift indels and nonsense mutations (Figure 2), 
consistent with its crucial role in the ER signaling pathway. One of the most recurrently mutated 
genes was E-cadherin (CDH1), with the hotspot truncating mutation in position 23 associated to the 
lobular histology (Figure 2). The prevalence of human epidermal growth factor receptor (HER)2-
mutant cases was higher in PR− breast cancers, albeit nonsignificant (n = 151, 16% vs. n = 389, 15%; p 
= 0.530). According to the Student’s t-test, the mutational profile of PR− Luminal breast cancers was 
significantly different to that of PR+ tumors (p < 10−5), with 16 mutations being restricted to the 
ER+/PR− group, including mutations in ARID1A, ATR, BCL6, BRAF, CARD11, CDH1, AXIN2, GATA3, 
MUC16, CCDC82, RUNX1, and TBX3 (Table 2). No significant correlations were observed between 
PR activation status and other clinicopathologic characteristics. The tumor mutational burden 
(median of five mutations per sample for both PR+/−; mean 15.2 per sample for PR+; mean 15.9 per 
sample for PR−; range 1–3474 in PR+; and range 1–2900 in PR−) of the cases included in this study is 
shown in Figure S3. 
 
Figure 2. Type of mutations and affected protein domains of the 10 most frequently altered genes in 
ER+/PR− breast cancers. Mutation types are color-coded on the basis of the legend at the bottom. 
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Table 2. The 37 recurrent mutations showing significant differences between ER+/PR− and ER+/PR+ 
breast cancers according to the test of Equal or Given Proportions. 
Mutation PR+ (%) PR− (%) p value 
ARID1A_Q766SfsX67 0 2 (0.20) 0.019 
ATR_A14S 0 2 (0.20) 0.019 
BCL6_K474EfsX26 0 2 (0.20) 0.019 
BRAF_V600E 0 2 (0.20) 0.019 
CARD11_D200E 0 2 (0.20) 0.019 
CDH1_R598X 0 2 (0.20) 0.019 
CDH1_E138X 0 2 (0.20) 0.019 
CDH1_E497RfsX25 0 2 (0.20) 0.019 
AXIN2_S493L 0 3 (0.31) 0.004 
GATA3_R364T 0 3 (0.31) 0.005 
CDH1_V202CfsX7 0 3 (0.31) 0.006 
MUC16_T7149A 0 3 (0.31) 0.007 
CCDC82_E175del 0 3 (0.31) 0.008 
RUNX1_D123GfsX15 0 4 (0.41) <0.001 
TBX3_W113X 0 4 (0.41) <0.001 
CDH1_T115NfsX53 1 (0.04) 3 (0.31) 0.029 
FOXA1_D226N 1 (0.04) 3 (0.31) 0.029 
FOXA1_I176M 1 (0.04) 3 (0.31) 0.029 
GATA3_X444LfsX63 1 (0.04) 3 (0.31) 0.029 
TERT_Promoter 1 (0.04) 3 (0.31) 0.029 
TP53_P278S 1 (0.04) 3 (0.31) 0.029 
SMAD4_Q245X 1 (0.04) 3 (0.31) 0.029 
TP53_I195T 1 (0.04) 5 (0.52) 0.002 
ERBB2_E770_A771insGIRD 1 (0.04) 8 (0.83) 0.003 
ERBB2_S310F 2 (0.08) 4 (0.41) 0.027 
MAP3K1_R364W 2 (0.08) 4 (0.41) 0.027 
TP53_H179R 2 (0.08) 4 (0.41) 0.027 
TP53_R342X 5 (0.19) 7 (0.72) 0.013 
GATA3_D335GfsX17 16 (0.61) 13 (1.35) 0.028 
TP53_R175H 21 (0.80) 18 (1.87) 0.006 
ESR1_Y537S 29 (1.11) 3 (0.31) 0.024 
ESR1_D538G 47 (1.80) 7 (0.72) 0.020 
SF3B1_K700E 60 (2.29) 10 (1.04) 0.016 
GATA3_X308_splice 70 (2.68) 9 (0.94) 0.002 
AKT1_E17K 106 (4.05) 25 (2.60) 0.04 
PIK3CA_E545K 251 (9.61) 68 (7.09) 0.019 
PIK3CA_H1047R 482 (18.46) 134 (13.97) 0.002 
2.2. The Prognostic Role of PIK3CA and TP53 in ER+/PR− Breast Cancers 
Overall, the highest mortality was observed before 50 months from the diagnosis, regardless of 
PR status, with a median survival of 76.9 months in PR− and 61 months in PR+ tumors. The most 
recurrently mutated genes in ER+/PR− and ER+/PR+ breast cancers were used to define the survival 
probability curves shown in Figure S4 and Figure S5, respectively. Even though the log-rank p-values 
were significant for TP53 and GATA3 mutations in both groups, survival analyses including tumors 
harboring alterations only in each of the most frequently mutated genes, but not in the others, 
revealed that in ER+/PR− breast cancers only TP53 mutations are related to a different prognosis 
(Figure 3). The hotspot regions of TP53 that were significantly different in PR− tumors were not 
related to a different outcome (Figure S6), similar to PIK3CA (Figure S7).  
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Figure 3. Overall survival of ER+/PR− (A) and ER+/PR+ (B) breast cancer patients based on TP53, 
PIK3CA, and GATA3 gene alterations. For each analysis, all samples harboring mutations in one of 
the other two genes were excluded. Survival curves are built according to the Kaplan–Meier method. 
Subsequently, survival curves were built according to the four molecular clusters identified on 
the basis of PIK3CA and TP53 status. These analyses revealed the prognostic value of the combination 
and mutual exclusivity of PIK3CA and TP53 mutations (Figure 4). Specifically, Cluster 4 showed in 
both PR− and PR+ cases a good prognosis. Interestingly, the prognosis of Cluster 4 overlapped to that 
of Cluster 3 in PR+ but not in PR− tumors. Hence, PR− breast cancers showed a different scenario, 
where the long-term outcome of the patients was worse in the presence of PIK3CA and/or TP53 
mutations (i.e., Clusters 1, 2 and 3). 
 
Figure 4. Overall survival of PIK3CA/TP53-mutant (Cluster 1), PIK3CAmutant/TP53 wild-type 
(Cluster 2), PIK3CA wild-type/TP53-mutant (Cluster 3), and PIK3CA/TP53 wild-type (Cluster 4) ER+ 
breast cancers, based on PR activation. Survival curves are built according to the Kaplan–Meier 
method. 
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3. Discussion 
The precise risk stratification in Luminal breast cancer by means of immunohistochemistry 
and/or prognostic genomic tests is a major limitation in defining the most appropriate management 
scheme [27]. Patients with ER+ breast cancers are assumed to have a good prognosis, but the lack of 
PR expression may contribute to their poor outcomes. This may be a result of the de-differentiation 
of hormone-positive neoplasms and subsequent development of resistance phenomena to both anti-
estrogen therapy and chemotherapy. Studies aiming to explore the genetic alterations in ER+/PR− 
breast cancers have been performed. However, the unique biology and challenging clinical course of 
these tumors, particularly in long-term survivors, suggest that they warrant further characterization. 
In this study, we analyzed a large cohort of PR− Luminal breast cancers with publicly available 
genomic data and compared their molecular landscape and prognosis to those of PR+ tumors. 
Altogether, we observed that several alterations in clinically actionable cancer genes are private to or 
enriched for in PR− breast cancers, such as TP53 R342X, P728S, I195T, and H179R, GATA3, CDH1, 
HER2, CDH1, and BRAF V600E. Furthermore, we identified four molecular clusters on the basis of 
PIK3CA and TP53 status with significantly different risk of death in PR− tumors. 
Decreased expression and/or downregulation of PR in breast cancer leads to a subset of tumors 
that is phenotypically ER+/PR−. Even though several hypotheses to explain this phenomenon have 
been put forward, we are still far from fully understanding its biology. In a proportion of Luminal 
tumors, ER, although expressed, is biologically nonfunctional and therefore it is unable to stimulate 
PR production, particularly in postmenopausal women [1]. Another mechanism for PR loss is the 
epigenetic inactivation of its promoter through hypermethylation [12]. Even though a genetic loss of 
a PR gene locus has previously been observed [12], in our analysis, all ER+/PR− tumors are PR wild-
type, suggesting that PR downregulation may be determined by growth factor pathways, as 
previously observed [2,11]. In particular, the HER2 activity may lead to the cytoplasmic sequestration 
of ER, which alters a set of genes that are normally regulated by ER, including PR−related genes, such 
as PIK3CA [11,28,29].  
Taken together, we observed that the most frequently mutated genes in ER+/PR− breast cancers 
are PIK3CA, TP53, GATA3, CHD1, KMT2C, MUC16, MAP3K1, ARID1A, AHNAK2, and SYNE2. 
Interestingly, PIK3CA and TP53 show a mutational prevalence (37% and 33%, respectively) that 
differs significantly to that of ER+/PR+ tumors (with PIK3CA mutated in 47% of cases and TP53 in 
19%). Those aspects have already been described in the literature [30,31]. On the other hand, the 
identification of a mutational profile specific to ER+/PR− cases, with 16 mutations being restricted to 
this group, is a novel finding. In our study, we confirm the presence of highly recurrent molecular 
alterations of the PIK3CA gene in position 1047, which likely constitute the driving genetic event in 
the pathogenesis of a subset of ER+/PR− breast cancers. These data provide further credence to the 
notion that inhibitors of this pathway (e.g., XL147) could reverse PR downregulation and overcome 
resistance to anti-HER2 drugs [32]. In addition, the identification of the BRAF V600E as a private 
mutation of PR− cases have possible therapeutic implications [33,34]. Recently, mutations in HER2 
have been detected in breast cancer patient samples which lack HER2 gene amplification. Thirteen 
HER2 mutations were characterized from twenty-five patient samples which had HER2 mutations 
but lacked HER2 gene amplification. Among them, seven mutations were activating and resulted 
from point mutations and in-frame deletions. Some mutations (L755S) resulted in lapatinib 
resistance; however, this was not an activating mutation. All of the cells containing the HER2 
mutations were sensitive to the irreversible HER2 kinase inhibitor, neratinib [35]. Our analysis 
corroborates the concept that mutations in GATA3 are associated with a better outcome in ER+ breast 
cancer patients [36]. After eliminating all cases with concurrent mutations in the other top recurrently 
mutated genes, however, we were able to confirm this notion only in PR+ tumors. These data suggest 
that GATA3 mutations are not an independent good prognostic factor in ER+/PR− tumors. Given that 
GATA3 is frequently altered in Luminal A breast cancers, our findings provide an additional 
molecular layer to the worse prognosis showed by ER+/PR− breast cancers [19,37]. Furthermore, we 
confirmed that TP53 mutations are associated with PR negativity and with a shorter overall survival 
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time in breast cancers [38]. Interestingly, this behavior is unrelated to the specific regions of TP53 that 
are recurrently altered in this subset of patients, akin to patients with PIK3CA-mutant tumors.  
The patterns of mutations in TP53 with PIK3CA allowed us to identify four molecular clusters 
in both PR− and PR+ Luminal breast cancers, namely PIK3CA/TP53-mutant (Cluster 1), PIK3CA-
mutant/TP53 wild-type (Cluster 2), PIK3CA wild-type/TP53-mutant (Cluster 3), and PIK3CA/TP53 
wild-type (Cluster 4). Notably, the prognostic distribution of these clusters differed substantially 
between ER+/PR− and ER+/PR+ breast cancers. Indeed, while in PR+ Luminal tumors Clusters 2 and 
4 were related to better survival, with overlapping curves, in PR− Luminal tumors Cluster 2 followed 
into in an intermediate risk category for the first 16 years of follow-up, becoming worse after that 
time. All these diverse correlations highlight the importance of PIK3CA and TP53 analysis in PR− 
Luminal breast cancer prognostication. 
4. Materials and Methods 
4.1. Case selection and Definitions 
We used the CGDS R package to interrogate the Cancer Genomics Data Server [39,40] and 
download mutational and clinical data related to three breast cancer projects hosted at the Memorial-
Sloan-Kettering Cancer Center: the METABRIC project [41], containing 2509 breast cancers samples; 
the MSK project [42] containing 1918 samples; and the TCGA project, containing 1105 samples. Each 
sample has both somatic mutational profiles for selected genes, and clinical information. In particular, 
the TCGA project contains mutational profiles for 20,461 genes, the METABTIC project contains 
mutational profiles for 173 genes and the MSK project for 474 genes. Moreover, we used gplots and 
ggplot2 packages [43,44] to perform the clustering analysis and visualize the data. We collected all 
somatic mutations related to the projects and integrated them to the clinical information and the 
treatment outcomes. Moreover, we selected all the estrogen receptor positive (ER+) samples reducing 
our dataset to 3589 samples, and a total of 53,585 somatic mutations in 13,402 genes.  
4.2. Statistical Analysis 
Comparisons between groups were generally performed using the Student’s t-test and test of 
Equal or Given Proportions. Event-free survival was expressed as the number of months from 
diagnosis to the occurrence of distant or local relapse or death (disease-related death). Cumulative 
survival probabilities were calculated using the Kaplan–Meier method. Differences between survival 
rates were tested with the log-rank test (SPSS version 20.0; IBM). Survival data were censored at five 
years. A p < 0.05 was considered statistically significant. Survival analysis and figures were developed 
using the R survival and survminer packages [45], and the Kaplan–Meier non-parametric statistic 
[46].  
5. Conclusion 
We demonstrated that ER+/PR− breast cancers are biologically characterized by relevant 
molecular characteristics in terms of prognostic and predictive information, which could be 
integrated into the clinical setting to realize the potentials of precision medicine in these clinically, 
and pathologically, challenging neoplasms.  
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/xxx/s1. Figure S1: 
Oncoprint visualization of highly recurrent somatic molecular alterations in ER+/PR+ breast cancers (2611 
samples). Each row represents a gene, as reported on the right and was sorted by gene alterations frequency (bar 
plot on the right); types of alterations are color-coded on the basis of the legend on the bottom. Each column 
represents a sample and was sorted to appreciate the mutual exclusivity across genes. The bar plot on the top 
represents the number of samples showing alterations in the displayed genes. Cluster analysis, HER2 status, 
histological type, tumor stage, and menopause status are reported as rows at the bottom of the figure; age at 
diagnosis is depicted in the top at the bottom. Clustering was performed according to the mutual exclusivity 
and patterns of mutations. Figure S2: Recurrent somatic alterations in 959 ER+/PR− (A) and in 2611 ER+/PR+ (B) 
breast cancers (2611 samples). Each row represents an alteration, as reported on the right, each column a sample. 
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Alterations were sorted by frequency, while the samples were sorted to appreciate the mutual exclusivity across 
alterations. Figures report the 50 most frequent gene alterations. Figure S3: Total number of mutations per 
samples in ER+/PR− (A) and ER+/PR+ (B) breast cancer patients. Each bar represents a sample; types of 
alterations are color-coded on the basis of the legend on the left. Figure S4: Overall survival of ER+/PR− breast 
cancer patients based on the most frequently altered genes. Survival curves (red, mutant; gray, wild-type) are 
built according to the Kaplan–Meier method. For each analysis, all samples harboring mutations in one of the 
other nine genes were excluded. Figure S5: Overall survival of ER+/PR+ breast cancer patients based on the most 
frequently altered genes. For each analysis, all samples harboring mutations in one of the other nine genes were 
excluded. Survival curves (red, mutant; gray, wild-type) are built according to the Kaplan–Meier method. Figure 
S6: Overall survival of ER+/PR− breast cancer patients based on the most frequently altered regions in the 
PIK3CA gene. Survival curves are built according to the Kaplan–Meier method. Figure S7: Overall survival of 
ER+/PR− breast cancer patients based on the most frequently altered regions in the TP53 gene. Survival curves 
are built according to the Kaplan–Meier method. Table S1: Mutations of the tumors included in the analysis. 
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